First-of-Its-Kind National Canine Cancer Registry Offers Ray of Hope to Dog Lovers | News Direct

First-of-Its-Kind National Canine Cancer Registry Offers Ray of Hope to Dog Lovers Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) provides vets and dog owners with important data to guide canine cancer diagnosis and treatment decisions

News release by YourUpdateTV

facebook icon linkedin icon twitter icon pinterest icon email icon New York, NY | June 21, 2022 05:00 PM Eastern Daylight Time

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop a tumor, and almost 50% of dogs over age 10 will develop cancer. Recently, Dr. Susan Ettinger, “Dr Sue Cancer Vet”, Veterinary Cancer Specialist and Take C.H.A.R.G.E. Scientific Advisory Board Member, and Lisa Conte, Jaguar Health Founder & CEO, conducted a satellite media tour to talk about the first-of-its-kind national canine cancer registry that offers a ray of hope to dog-lovers everywhere.

A video accompanying this announcement is available at: 

Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) provides vets and dog owners with important data to guide canine cancer diagnosis and treatment decisions

Designed to be interactive and with open access to academia, the Jaguar Health Canine Cancer: Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange), co-sponsored by Jaguar Animal Health, TogoRun, and Ivee, is a first-of-its-kind national Canine Cancer Registry and Canine Cancer Care Index that provides the veterinary community and canine pet owners with important incidence and prevalence data to help guide canine cancer diagnosis and treatment decisions, at no cost.

The Registry began with a retrospective review of more than 35,000 anonymous canine patient records uploaded into a secure customized database and more than 830 confirmed cancer diagnoses and is interactive. Protecting dogs from cancer begins with knowing its impact by breed, type, age, gender, and location

Powered by animal health software company Ivee (Intelligent Veterinary Enhanced Experience), only information from canine patients that have been diagnosed with cancer is accessed and data is continuously protected. All research and academia related activities are de-identified and anonymized, following all General Data Protection Regulation (GDPR) guidelines, to ensure 100% participant and veterinary information protection.

Currently there is no published state-by-state registry in the U.S. documenting canine cancer, while there are multiple regional European registries that exist and serve to inform both the veterinary and human oncology communities.

The Registry also includes the first nationwide Gallup survey of pet owners addressing their experience with canine cancer. Canine Cancer Impact on Humans - Dealing with canine cancer has a major impact on dog owners’ well-being, including depression, anxiety, lack of sleep, and missing work or other obligations; for example, 63 percent of respondents reported feeling a lot of stress and 58 percent reported feeling down and depressed a lot during their dog's cancer. And, more than 8 in 10 dog owners favor the creation of a canine cancer registry to better understand the disease and advance treatments

The survey found that the incidence – the percent of U.S. dogs newly diagnosed with cancer in 2021 – was approximately five times incidence of newly diagnosed cancer in humans that year, which is startling since researchers have assumed that canine cancer rates mirror human cancer rates.

A complementary Index was established based on pet owner responses to this multi-year nationwide Gallup survey assessing pet owner experience with their dog’s cancer diagnosis and treatment.

Together the Registry and Index provides the veterinary community with important information to guide canine cancer diagnosis and treatment decisions and support dog owners by improving canine cancer care.

The Gallup survey closed on March 30, 2022, with over 3,800 respondents, including over 600 responses from dog owners with canine cancer experience.

Canine cancer patient records uploaded to the Registry are updated regularly thanks to ongoing input from participating veterinarians and owners of dogs who have been diagnosed with cancer. If your dog passed away from cancer, you can contribute to building hope for all dog lovers by uploading your canine pet’s medical records as well.

How to get involved as a veterinarian:

· If you are a veterinarian and interested in having your clinic/practice opt into the Take C.H.A.R.G.E. Registry, please visit to fill out the Veterinarian Practice Registration form.

· All research and academia related activities will be de-identified and anonymized to ensure 100% participant and veterinary information protection.

· Once you opt in, the Take C.H.A.R.G.E. Registry will have access to all of your current and newly diagnosed canine patients with cancer. These files will be automatically uploaded into the Take C.H.A.R.G.E. Registry in real time, so no further action is needed once you opt in.

How to get involved as a dog owner:

· If you are a pet owner and have a PDF of your dog's medical records, simply upload them into the Registry by visiting

· If you do not have your dog's medical records, tell your veterinarian about the Registry at your next visit and encourage them to join!

· Follow us on our social channels and reshare with your friends!

@Take C.H.A.R.G.E.  




About Susan Ettinger

Dr. Sue Ettinger is a practicing veterinary cancer specialist, international speaker, book author, and vlogger (video blogger). She is one of approximately 450 board-certified specialists in medical oncology in North America and currently practices at Veterinary Referral and Emergency Center in Norwalk, Connecticut. She is co-founder and Chief Medical Officer of Fidu, a teleconsulting company to bring together general practice veterinarians and boarded veterinary specialists. She received her veterinary training at Cornell University College of Veterinary Medicine. She completed her residency in medical oncology at the Animal Medical Center in NYC in 2003.

She was voted the 2019 Western Veterinary Conference (WVC) Small Animal Continuing Educator of the Year and has recently received awards for Exceptional Doctor Performance and the Public Relations Achievement. Also known as Dr Sue Cancer Vet®, Dr. Sue is the co-author of the Second Edition of The Dog Cancer Survival Guide, which is a best-selling book in small animal health for the last several years. She is a frequent contributor to many veterinary publications, including Today’s Veterinary Practice, Today’s Veterinary Business, Clinician’s Brief, Veterinary Team Brief, & DVM360. She also has co-hosted the podcast The Pet Cancer Vet and is a frequent guest on many veterinary podcasts. There are many myths and misconceptions about cancer in dogs and cats. Most cancers are treatable, and there are a variety of treatment options. Dr Sue’s focus is to provide comprehensive and compassionate care. She strives to minimize side effects – from the cancer itself and treatment – to help her patients lead active, normal lives even while undergoing treatment. Her motto is live longer, live well.

Dr. Sue is most passionate about raising cancer awareness, and she has developed “See Something, Do Something, Why Wait? Aspirate.®” to promote early cancer detection and diagnosis. This cancer awareness initiative for skin and superficial tumors in dogs and cats provides a set of guidelines for pet owners and veterinarians to help identify the best management for skin and subcutaneous (under the skin) masses in dogs and cats. Masses must be sampled and evaluated under a microscope to determine what they are. The sooner we determine whether a mass is cancerous and should be removed, the better for our pets. Most skin and subcutaneous tumors can be cured with surgery alone if diagnosed early when masses are small. Early detection saves lives.

Lisa Conte, Jaguar Health Founder & CEO

Lisa Conte is the founder, president and chief executive officer, and a member of the board of directors of Jaguar Health, a commercial-stage pharmaceuticals company committed to discovering, developing and commercializing plant-based prescription medicines for urgent global health needs. Mytesi®, the company’s FDA-approved drug product, is a first-in-class, plant-based anti-secretory agent and the first oral drug approved under FDA Botanical Guidance. In 1989, Ms. Conte also founded Shaman Pharmaceuticals, Inc. and has pioneered plant-based prescription medicine investigation and development for more than 30 years, including a recent Entheogen Therapeutics Initiative looking at psychoactive plants for novel cures for mental health disorders; and Napo Therapeutics, S.p.A., a company established in Italy with a focus on the treatment of rare diseases from plant-based prescription medicines under license from Jaguar Health. Ms. Conte is currently a member of the board of directors of the Healing Forest Conservatory and Napo Therapeutics, and serves on the Editorial Advisory Board of Life Science Leader magazine. She holds an M.S. in Physiology and Pharmacology from the University of California, San Diego, and an M.B.A. and A.B. in Biochemistry from Dartmouth College, and is also the parent of two Jack Russell Terriers and a Belgium Warmblood.




Contact Details




+1 212-736-2727